GI-102 + paclitaxel + bevacizumab

**GI-102 + paclitaxel + bevacizumab** is an investigational combination therapy being evaluated for advanced and/or metastatic solid tumors in clinical trials, particularly in immuno-oncology contexts. - **GI-102** is a next-generation immunocytokine, specifically a bi-specific Fc fusion protein containing the CD80 ectodomain and an interleukin-2 variant (IL-2v), configured via a human IgG4 Fc. GI-102 targets CD80 and IL-2Rβγ, thus directly stimulating immune cell activation while minimizing regulatory T cell (Treg) proliferation by abolishing IL-2Rα affinity. This leads to robust proliferation and activation of NK and CD8+ T cells, with expected anti-tumor effects[5][7][3]. GI-102 also blocks CTLA-4 on Tregs and can inhibit PD-L1/CTLA-4 via the CD80 component[7]. - **Paclitaxel** is a microtubule-stabilizing antineoplastic (chemotherapy) drug that inhibits cell division by binding to tubulin. - **Bevacizumab** is an an anti-VEGF-A monoclonal antibody that inhibits angiogenesis, thereby starving tumors of blood supply[2][4]. This regimen is under clinical investigation by GI Innovation and partners at leading global oncology centers, primarily for patients with advanced cancers such as metastatic melanoma, liver cancer, and renal cell carcinoma, often refractory to prior immuno- or chemo- therapies[5][1][3][6].